Bill · HR
H.R. 2821 (119th)
FDA Modernization Act 3.0
Original
Introduced
10 April 2025
Last action
21 July 2026 · Introduced
Status
Received in the Senate.
Sponsors
Rep. Carter, Earl L. "Buddy" [R-GA-1], Nanette Barragán, Rep. Buchanan, Vern [R-FL-16], Rosa DeLauro, Diana Harshbarger, Troy Carter, Lloyd Doggett, Jerrold Nadler, Mike Carey, Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Malliotakis, Nicole [R-NY-11], Rep. Crenshaw, Dan [R-TX-2], Judy Chu, Hillary Scholten, Darren Soto, Daniel Goldman, Jay Obernolte, Rep. Gottheimer, Josh [D-NJ-5], Jason Crow, Ted Lieu, Rep. Tenney, Claudia [R-NY-24], Rep. Smith, Christopher H. [R-NJ-4], Del. Norton, Eleanor Holmes [D-DC-At Large], Maria Salazar, Lois Frankel, David Valadao, Josh Harder, Rep. Fitzgerald, Scott [R-WI-5], Rep. Bilirakis, Gus M. [R-FL-12], Laurel Lee, Rep. Calvert, Ken [R-CA-41], Rep. Vindman, Eugene Simon [D-VA-7], Mark Pocan, Rep. Lawler, Michael [R-NY-17], Rep. Weber, Randy K. Sr. [R-TX-14], Rep. Neguse, Joe [D-CO-2], Raja Krishnamoorthi, Thomas Kean, Julie Johnson, Young Kim, Nicholas Langworthy, Shri Thanedar
Subjects
Healthcare
Source updated
20 August 2026
Summary
FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
10 April 2025
Introduced
Referred to the House Committee on Energy and Commerce.
Source: IntroReferral
10 April 2025
Introduced
Introduced in House
Source: IntroReferral
10 April 2025
Introduced
Introduced in House
Source: IntroReferral
10 April 2026
Referred
Referred to the Subcommittee on Health.
Source: Committee
13 May 2026
Committee
Forwarded by Subcommittee to Full Committee by Voice Vote.
Source: Committee
13 May 2026
Committee
Subcommittee Consideration and Mark-up Session Held
Source: Committee
21 May 2026
Vote
Ordered to be Reported by the Yeas and Nays: 44 - 0.
Source: Committee
21 May 2026
Committee
Committee Consideration and Mark-up Session Held
Source: Committee
18 June 2026
Calendars
Placed on the Union Calendar, Calendar No. 614.
Source: Calendars
18 June 2026
Reported
Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
Source: Committee
18 June 2026
Reported
Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
Source: Committee
20 July 2026
Passed
Motion to reconsider laid on the table Agreed to without objection.
Source: Floor
20 July 2026
Passed
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H4639)
Source: Floor
20 July 2026
Passed
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H4639)
Source: Floor
20 July 2026
Floor
DEBATE - The House proceeded with forty minutes of debate on H.R. 2821.
Source: Floor
20 July 2026
Floor
Considered under suspension of the rules. (consideration: CR H4639-4640)
Source: Floor
20 July 2026
Floor
Mr. Guthrie moved to suspend the rules and pass the bill.
Source: Floor
21 July 2026
Introduced
Received in the Senate.
Source: IntroReferral
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
4 official files
Engrossed in House
Engrossed in House · EN · 20 July 2026
Reported in House
Reported in House · EN · 18 June 2026
Introduced in House
Introduced in House · EN · 10 April 2025
Introduced in House
summary · EN · 10 April 2025
Sponsors
- Rep. Carter, Earl L. "Buddy" [R-GA-1] · R · Sponsor
- Nanette Barragán · D · Sponsor
- Rep. Buchanan, Vern [R-FL-16] · R · Sponsor
- Rosa DeLauro · D · Sponsor
- Diana Harshbarger · R · Sponsor
- Troy Carter · D · Sponsor
- Lloyd Doggett · D · Cosponsor
- Jerrold Nadler · D · Cosponsor
- Mike Carey · R · Cosponsor
- Rep. Fitzpatrick, Brian K. [R-PA-1] · R · Cosponsor
- Rep. Malliotakis, Nicole [R-NY-11] · R · Cosponsor
- Rep. Crenshaw, Dan [R-TX-2] · R · Cosponsor
- Judy Chu · D · Cosponsor
- Hillary Scholten · D · Cosponsor
- Darren Soto · D · Cosponsor
- Daniel Goldman · D · Cosponsor
- Jay Obernolte · R · Cosponsor
- Rep. Gottheimer, Josh [D-NJ-5] · D · Cosponsor
- Jason Crow · D · Cosponsor
- Ted Lieu · D · Cosponsor
- Rep. Tenney, Claudia [R-NY-24] · R · Cosponsor
- Rep. Smith, Christopher H. [R-NJ-4] · R · Cosponsor
- Del. Norton, Eleanor Holmes [D-DC-At Large] · D · Cosponsor
- Maria Salazar · R · Cosponsor
- Lois Frankel · D · Cosponsor
- David Valadao · R · Cosponsor
- Josh Harder · D · Cosponsor
- Rep. Fitzgerald, Scott [R-WI-5] · R · Cosponsor
- Rep. Bilirakis, Gus M. [R-FL-12] · R · Cosponsor
- Laurel Lee · R · Cosponsor
- Rep. Calvert, Ken [R-CA-41] · R · Cosponsor
- Rep. Vindman, Eugene Simon [D-VA-7] · D · Cosponsor
- Mark Pocan · D · Cosponsor
- Rep. Lawler, Michael [R-NY-17] · R · Cosponsor
- Rep. Weber, Randy K. Sr. [R-TX-14] · R · Cosponsor
- Rep. Neguse, Joe [D-CO-2] · D · Cosponsor
- Raja Krishnamoorthi · D · Cosponsor
- Thomas Kean · R · Cosponsor
- Julie Johnson · D · Cosponsor
- Young Kim · R · Cosponsor
- Nicholas Langworthy · R · Cosponsor
- Shri Thanedar · D · Cosponsor
- · hsif00 · Standing
Related records
- related to → FDA Modernization Act 3.0
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/119th-congress/house-bill/2821
- Open data entity: https://api.congress.gov/v3/bill/119/hr/2821
- us · 119-hr-2821 · source updated 20 August 2026